Evotec SE

XETRA EVT.DE

Evotec SE Price to Earnings Ratio (P/E) on January 14, 2025: -15.51

Evotec SE Price to Earnings Ratio (P/E) is -15.51 on January 14, 2025, a 56.78% change year over year. Price to earnings ratio compares the stock price to earnings per share; higher P/E suggests expectations for future earnings growth.

Evotec SE 52-week high Price to Earnings Ratio (P/E) is -11.00 on October 15, 2024, which is 29.08% above the current Price to Earnings Ratio (P/E).
Evotec SE 52-week low Price to Earnings Ratio (P/E) is -35.88 on January 15, 2024, which is -131.38% below the current Price to Earnings Ratio (P/E).
Evotec SE average Price to Earnings Ratio (P/E) for the last 52 weeks is -19.82.

Key data

Date	Price to Earnings Ratio (P/E)	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield

XETRA: EVT.DE

Evotec SE

CEO	Dr. Christian Wojczewski
IPO Date	Nov. 12, 1999
Location	Germany
Headquarters	Essener Bogen 7
Employees	5,007
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as diabetes and complications of diabetes, fibrosis, infectious diseases, CNS diseases, oncology, pain and inflammation, immunology, rare diseases, respiratory diseases, and women's health. It has collaboration agreements with Bayer AG; Lilly; Chinook Therapeutics; Novo Nordisk A/S; Galapagos; Pfizer Inc.; CONBA Pharmaceutical Co., Ltd.; Bristol Myers Squibb Company; Zhejiang JingXin Pharmaceutical Co., Ltd; Kazia Therapeutics; Apeiron Biologics; and Takeda Pharmaceuticals. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.

Key trends

Past 5 years